DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ophthetic (Proparacaine Hydrochloride Ophthalmic) - Summary



(proparacaine HCI ophthalmic solution) 0.5%

OPHTHETIC® (proparacaine HCI ophthalmic solution) 0.5% is a topical local anesthetic for ophthalmic use.

OPHTHETIC® ophthalmic solution is indicated for procedures in which a topical ophthalmic anesthetic is indicated: corneal anesthesia of short duration, e.g., tonometry, gonioscopy, removal of corneal foreign bodies, and for short corneal and conjunctival procedures.

See all Ophthetic indications & dosage >>


Media Articles Related to Ophthetic (Proparacaine Ophthalmic)

Studies reveal how anesthesia's brain effects differ in older adults and in children
Source: Pain / Anesthetics News From Medical News Today [2015.08.14]
Age-related EEG patterns correspond with neurophysiological changes associated with development, agingRecent Massachusetts General Hospital (MGH) investigations into the neurobiology underlying...

Surgery Patients Might Not Need Sedative Before Anesthesia
Source: MedicineNet lorazepam Specialty [2015.03.04]
Title: Surgery Patients Might Not Need Sedative Before Anesthesia
Category: Health News
Created: 3/3/2015 12:00:00 AM
Last Editorial Review: 3/4/2015 12:00:00 AM

more news >>

Published Studies Related to Ophthetic (Proparacaine Ophthalmic)

Dilute proparacaine for the management of acute corneal injuries in the emergency department. [2010.09]
OBJECTIVE: Dogma discourages the provision of topical anesthetics to patients with corneal injuries discharged from the emergency department because of the toxicity of concentrated solutions. We compared the analgesic efficacy of dilute topical proparacaine with placebo in emergency department patients with acute corneal injuries... CONCLUSION: Dilute topical proparacaine is an efficacious analgesic for acute corneal injuries. Although no adverse events were observed in our study population, larger studies are required to evaluate safety.

Subtenon lidocaine vs topical proparacaine in adult strabismus surgery. [2006.09]
Intraoperative subtenon 2% lidocaine and topical 0.5% proparacaine in patients undergoing strabismus surgery were compared. No additional systemic analgesics and sedatives were used.Topical 0.5% proparacaine may be preferred because of its easy administration and fewer side effects, lack of hospital admission, and immediate and predictable alignment of the eyes.

Duration of effect and effect of multiple doses of topical ophthalmic 0.5% proparacaine hydrochloride in clinically normal dogs. [2005.01]
OBJECTIVE: To determine the duration of effect and the effect of multiple doses of topical ophthalmic application of 0.5% proparacaine hydrochloride on corneal sensitivity in clinically normal dogs...

A randomised comparison of lidocaine 2% gel and proparacaine 0.5% eye drops in paediatric squint surgery. [2013]
We conducted a randomised trial comparing lidocaine 2% gel with proparacaine 0.5% eye drops in children having elective squint surgery. One hundred and forty children aged between 3 and 14 years were recruited... We conclude that, compared with proparacaine 0.5% eye drops, a single application of lidocaine 2% gel improves peri-operative analgesia and reduces the incidence of postoperative nausea and vomiting in elective paediatric squint surgery.

Effect of a proparacaine 0.50%-sodium fluorescein 0.25% mix and contact ultrasound pachymetry on central and midperipheral corneal thickness measured by noncontact optical pachymetry. [2011.05]
PURPOSE: To assess the effect of a combination of proparacaine 0.50%-sodium fluorescein 0.25% and ultrasound (US) pachymetry on central and midperipheral corneal thickness. SETTING: School of Optometry and Vision Sciences, Cardiff University, Cardiff, Wales, United Kingdom... CONCLUSIONS: Ultrasound pachymetry combined with proparacaine 0.50%-sodium fluorescein 0.25% caused a small (<10 mum) but significant amount of corneal swelling on average. Because the effect on corneal thickness may be greater than -10 to +30 mum in individual cases, clinicians should avoid contact procedures before obtaining topographic maps of corneal thickness using scanning-slit and Scheimpflug devices. Copyright (c) 2011 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

more studies >>

Clinical Trials Related to Ophthetic (Proparacaine Ophthalmic)

Accu-Chek Combo in Young Patients [Not yet recruiting]
This is an open, prospective, descriptive study aiming to evaluate the change in treatment satisfaction of primary care givers of young children who use the Accu-Chek Combo System. Patients will routinely be scheduled and start their therapy with the Accu-Chek Combo System on visit 1. Twelve weeks later the final acquisition of data will occur. Diabetes Treatment Satisfaction Questionnaires (DTSQ) will be completed at baseline and after 12 weeks, a distinct acceptance questionnaires will be completed at final visit. In addition, Diabetes related therapeutic information will be collected and data about the use of the device components will be downloaded from the Accu-Chek Combo System

Proparacaine and Mydriatic Eye Drops [Recruiting]
In this study, we will be evaluating whether premedication with an anesthetic eye drops leads to a decreased sensation of pain when given dilating eye drops prior to eye examinations to evaluate for retinopathy of prematurity in neonatal intensive care unit (NICU) infants.

Clinical Assessment of an in-Patient Glucose Monitoring System (Accu-Chek Inform Cobas IT 1000) [Completed]
The principal objective of this single-center 2-period study is to evaluate the glycemic control of in-patients in 3 hospital departments (Diabetology, Cardiology and Pulmonary Care) as the rate of capillary blood glucose measurements within a pre-define target range, and to compare results during the period I (warning of the Accu-Check Inform glucose meter on glucose levels not activated) and period II (warning activated).

Proparacaine vs Placebo for Corneal Injuries [Completed]
Introduction: Traumatic injuries to the outer covering of the eye (the cornea) are a common emergency department complaint. They cause significant patient distress including pain, loss of sleep and missed work days. There is currently no accepted, uniform approach to pain management in this patient population. Emergency medicine and ophthalmology texts state that prolonged use of medications that anesthetize the cornea is not recommended. Several recent publications in the ophthalmology literature show that the outpatient use of dilute local anesthesia in patients after eye surgery is a safe and effective method of pain control. In this study, we used Proparacaine (a local anesthetic), in a similar manner, for the outpatient emergency department management of traumatic corneal injuries.

Methods: We performed a clinical trial on a sample of adult patients presenting with traumatic corneal injuries to two university affiliated emergency departments in London, Canada.

Patients providing signed informed consent to participate in the study received a vial of clear liquid that contained either Proparacaine or plain water (placebo), a pain log, topical antibiotics and oral Acetaminophen (Tylenol) with Codeine for breakthrough pain.

Patients were instructed to use the "study drug" on an "as-needed" basis for the next seven days. Patients completed a pain scale describing their discomfort immediately prior to, and five minutes after self-administration of the study drug. All patients were followed closely in an ophthalmology outpatient clinic on Days 1, 3 and 5 after presentation to the emergency department. At the last ophthalmology clinic visit, the patients' pain logs were collected.

The protocol was approved by the Research Ethics Board for Health Sciences Research Involving Human Subjects at the University of Western Ontario.

Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized Study [Recruiting]
COMPASS is a status and intervention study for the self-monitoring of blood glucose (SMBG) in type 2 diabetic patients with insulin treatment. This multi-centre, open-label prospective study will assess the use and frequency of SMBG and blood glucose control and its influencing factors with the help of Accu-Chek Integra glucometer. Patients with type 2 diabetes mellitus who have received more than 3 months of insulin therapy are eligible to participate in this study. The anticipated duration of the study is 6 months.

more trials >>

Page last updated: 2015-08-14

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015